Sun Pharma's LEQSELVI Shows Sustained Efficacy in Severe Alopecia Areata Over Two Years
Sun Pharma's LEQSELVI® (deuruxolitinib) showed sustained efficacy and safety over two years in severe alopecia areata patients at the EADV Congress 2026. Long-term data indicated durable scalp hair regrowth and a consistent safety profile. The drug is an oral selective inhibitor of Janus kinases JAK1 and JAK2.
The announcement pertains to ongoing clinical data presentation for an existing drug, which may reinforce its market position and physician confidence but does not represent a new drug approval or a significant financial event.
The announcement highlights positive long-term efficacy and safety data for LEQSELVI, suggesting it is a viable treatment option for severe alopecia areata.
Sun Pharmaceutical Industries Limited announced that LEQSELVI® (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. A key oral presentation highlighted that the drug's safety profile remained consistent through up to two years of open-label treatment in adults with severe alopecia areata (AA). Most treatment-emergent adverse events were mild to moderate, with uncommon discontinuations due to adverse events and no reported deaths, thrombosis, or major adverse cardiovascular events at the FDA-approved dose of 8 mg twice daily.
Further efficacy analyses demonstrated durable scalp hair regrowth through Week 108. Among baseline treatment responders (SALT score ≤20) who maintained response at Week 52 and continued in the study, 93.9% sustained their response at Week 108. For baseline non-responders (SALT score >20), 76.6% achieved response by Week 52, and of those who continued, 96.8% maintained that response at Week 108. The data also showed consistent efficacy across various patient subgroups in pooled post hoc analyses of THRIVE-AA1 and THRIVE-AA2 studies.
Dr. Arash Mostaghimi noted the long-term data support deuruxolitinib as a viable treatment option for eligible adults with severe alopecia areata, a chronic autoimmune disease. Ahmad Naim, MD, Senior Vice President and North America Chief Medical Officer at Sun Pharma, emphasized the commitment to advancing research for unmet needs in this condition.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.